AI Article Synopsis
- This study looked at how well a medication called lisdexamfetamine (LDX) works for people with binge-eating disorder (BED) after they had a successful initial treatment.
- Sixty-one adults took part, and they were split into two groups: one group took LDX while the other got a placebo (a fake pill) for 12 weeks.
- Results showed that fewer people who took LDX returned to binge eating compared to those who took the placebo, and the LDX group also lost weight, while the placebo group gained weight.
Article Abstract
Background: Controlled research examining maintenance treatments for responders to acute interventions for binge-eating disorder (BED) is limited. This study tested efficacy of lisdexamfetamine (LDX) maintenance treatment amongst acute responders.
Methods: This prospective randomized double-blind placebo-controlled single-site trial, conducted March 2019 to September 2023, tested LDX as maintenance treatment for responders to acute treatments with LDX-alone or with cognitive-behavioral therapy (CBT + LDX) for BED with obesity. Sixty-one (83.6% women, mean age 44.3, mean BMI 36.1 kg/m) acute responders were randomized to LDX ( = 32) or placebo ( = 29) for 12 weeks; 95.1% completed posttreatment assessments. Mixed-models and generalized-estimating equations comparing maintenance LDX placebo included main/interactive effects of acute (LDX or CBT + LDX) treatments to examine their predictive/moderating effects.
Results: Relapse rates (to diagnosis-level binge-eating frequency) following maintenance treatments were 10.0% ( = 3/30) for LDX and 17.9% ( = 5/28) for placebo; intention-to-treat binge-eating remission rates were 59.4% ( = 19/32) and 65.5% ( = 19/29), respectively. Maintenance LDX and placebo did not differ significantly in binge-eating but differed in weight-loss and eating-disorder psychopathology. Maintenance LDX was associated with significant weight-loss (-2.3%) whereas placebo had significant weight-gain (+2.2%); LDX and placebo differed significantly in weight-change throughout treatment and at posttreatment. Eating-disorder psychopathology remained unchanged with LDX but increased significantly with placebo. Acute treatments did not significantly predict/moderate maintenance-treatment outcomes.
Conclusions: Adults with BED/obesity who respond to acute lisdexamfetamine treatment (regardless of additionally receiving CBT) had good maintenance during subsequent 12-weeks. Maintenance lisdexamfetamine, relative to placebo, did not provide further benefit for binge-eating but was associated with significantly better eating-disorder psychopathology outcomes and greater weight-loss.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496227 | PMC |
| http://dx.doi.org/10.1017/S003329172400148X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial.
Psychol Med
September 2024
Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
Article Synopsis
- This study looked at how well a medication called lisdexamfetamine (LDX) works for people with binge-eating disorder (BED) after they had a successful initial treatment.
- Sixty-one adults took part, and they were split into two groups: one group took LDX while the other got a placebo (a fake pill) for 12 weeks.
- Results showed that fewer people who took LDX returned to binge eating compared to those who took the placebo, and the LDX group also lost weight, while the placebo group gained weight.
Neurobiological basis of reinforcement-based decision making in adults with ADHD treated with lisdexamfetamine dimesylate: Preliminary findings and implications for mechanisms influencing clinical improvement.
J Psychiatr Res
February 2024
Center for Neurobehavioral Research, Boys Town National Research Hospital, Boys Town, NE, 68010, USA.
Article Synopsis
- The study investigates how treatment with lisdexamfetamine (LDX) affects brain reward system activation in adults with ADHD, focusing on whether clinical improvements are linked to changes in reward-related mechanisms.
- Participants underwent fMRI scans after receiving LDX and a placebo, allowing researchers to assess brain activation during tasks related to reward learning.
- Results showed that symptom improvement was associated with increased brain activation in areas connected to reinforcement processing, suggesting a positive relationship between LDX treatment and reward sensitivity in ADHD patients.
Binge-Eating Disorder Interventions: Review, Current Status, and Implications.
Curr Obes Rep
September 2023
Department of Psychological and Brain Sciences, Drexel University, Philadelphia, PA, USA.
Purpose Of Review: Binge-eating disorder (BED) is a serious psychiatric problem associated with substantial morbidity that, unfortunately, frequently goes unrecognized and untreated. This review summarizes the current status of behavioral, psychological, pharmacological, and combined treatments for BED in adults with a particular focus on recent findings and advances.
Recent Findings: Certain specific psychological treatments, notably CBT and IPT, and to some extent DBT, have demonstrated efficacy and are associated with durable benefits after treatment.
analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders.
Front Endocrinol (Lausanne)
July 2023
Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Aim: In a recent randomized, multicenter trial (NCT02814838) a short-term anti-inflammatory treatment with ladarixin (LDX; an inhibitor of the CXCR1/2 chemokine receptors) did not show benefit on preserving residual beta cell function in new-onset type 1 diabetes. We present a analysis of trial patients in the predefined subgroup analysis developed according to baseline daily insulin requirement (DIR) tertiles.
Method: A double-blind, randomized (2:1), placebo-controlled study was conducted in 45 men and 31 women (aged 18-46 years) within 100 days of the first insulin administration.
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab
September 2022
Research and Development, Dompé farmaceutici S.p.A, Milan, Italy.
Aim: To evaluate the ability of ladarixin (LDX, 400 mg twice-daily for three cycles of 14 days on/14 days off), an inhibitor of the CXCR1/2 chemokine receptors, to maintain C-peptide production in adult patients with newly diagnosed type 1 diabetes.
Materials And Methods: A double-blind, randomized (2:1), placebo-controlled study was conducted in 45 males and 31 females (aged 18-46 years) within 100 days of the first insulin administration. The primary endpoint was the area under the curve (AUC) for C-peptide in response to a 2-hour mixed meal tolerance test (AUC ) at week 13 ± 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!